He has designed and synthesised selective drugs for breast and prostate cancer at the UK's Institute of Cancer Research. His prostate cancer drug, abiraterone acetate, has been licensed as a last-line treatment for prostate cancer — not an easy task, …
(Visited 4 times, 1 visits today)
){kind=link}
Comments
Comments are disabled for this post.